These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35642869)

  • 1. Restoration of the Immunogenicity of Tumor Cells for Enhanced Cancer Therapy via Nanoparticle-Mediated Copper Chaperone Inhibition.
    Ding F; Li F; Tang D; Wang B; Liu J; Mao X; Yin J; Xiao H; Wang J; Liu Z
    Angew Chem Int Ed Engl; 2022 Aug; 61(31):e202203546. PubMed ID: 35642869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of copper chaperones sensitizes human and canine osteosarcoma cells to carboplatin chemotherapy.
    Inkol JM; Poon AC; Mutsaers AJ
    Vet Comp Oncol; 2020 Dec; 18(4):559-569. PubMed ID: 32060984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidation of Human Copper Chaperone Atox1 and Disulfide Bond Cleavage by Cisplatin and Glutathione.
    Nardella MI; Rosato A; Belviso BD; Caliandro R; Natile G; Arnesano F
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cuprous oxide nanoparticles trigger ER stress-induced apoptosis by regulating copper trafficking and overcoming resistance to sunitinib therapy in renal cancer.
    Yang Q; Wang Y; Yang Q; Gao Y; Duan X; Fu Q; Chu C; Pan X; Cui X; Sun Y
    Biomaterials; 2017 Nov; 146():72-85. PubMed ID: 28898759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Light triggered release of a triple action porphyrin-cisplatin conjugate evokes stronger immunogenic cell death for chemotherapy, photodynamic therapy and cancer immunotherapy.
    Song H; Cai Z; Li J; Xiao H; Qi R; Zheng M
    J Nanobiotechnology; 2022 Jul; 20(1):329. PubMed ID: 35842642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of Copper and Cisplatin to Atox1 Is Mediated by Glutathione through the Formation of Metal-Sulfur Clusters.
    Dolgova NV; Yu C; Cvitkovic JP; Hodak M; Nienaber KH; Summers KL; Cotelesage JJH; Bernholc J; Kaminski GA; Pickering IJ; George GN; Dmitriev OY
    Biochemistry; 2017 Jun; 56(24):3129-3141. PubMed ID: 28549213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Near-infrared light triggered activation of pro-drug combination cancer therapy and induction of immunogenic cell death.
    Kang X; Cai Y; Wang Q; Wang C; Chen W; Yang W; Suryawanshi A; Zhou G; Chen P; Li F
    Int J Pharm; 2021 Sep; 607():120972. PubMed ID: 34363916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyphotosensitizer-Based Nanoparticles with Michael Addition Acceptors Inhibiting GST Activity and Cisplatin Deactivation for Enhanced Chemotherapy and Photodynamic Immunotherapy.
    Zhao Q; Liang G; Guo B; Wang W; Yang C; Chen D; Yang F; Xiao H; Xing N
    Adv Sci (Weinh); 2023 May; 10(13):e2300175. PubMed ID: 36930173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin binds human copper chaperone Atox1 and promotes unfolding in vitro.
    Palm ME; Weise CF; Lundin C; Wingsle G; Nygren Y; Björn E; Naredi P; Wolf-Watz M; Wittung-Stafshede P
    Proc Natl Acad Sci U S A; 2011 Apr; 108(17):6951-6. PubMed ID: 21482801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic and Structural Basis for Inhibition of Copper Trafficking by Platinum Anticancer Drugs.
    Lasorsa A; Nardella MI; Rosato A; Mirabelli V; Caliandro R; Caliandro R; Natile G; Arnesano F
    J Am Chem Soc; 2019 Jul; 141(30):12109-12120. PubMed ID: 31283225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distorted copper homeostasis with decreased sensitivity to cisplatin upon chaperone Atox1 deletion in Drosophila.
    Hua H; Günther V; Georgiev O; Schaffner W
    Biometals; 2011 Jun; 24(3):445-53. PubMed ID: 21465178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interference between copper transport systems and platinum drugs.
    Arnesano F; Natile G
    Semin Cancer Biol; 2021 Nov; 76():173-188. PubMed ID: 34058339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystal structures of cisplatin bound to a human copper chaperone.
    Boal AK; Rosenzweig AC
    J Am Chem Soc; 2009 Oct; 131(40):14196-7. PubMed ID: 19807176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression of copper transporters associated with the ototoxicity induced by platinum-based chemotherapeutic agents.
    Perde-Schrepler M; Fischer-Fodor E; Virag P; Brie I; Cenariu M; Pop C; Valcan A; Gurzau E; Maniu A
    Hear Res; 2020 Mar; 388():107893. PubMed ID: 32006874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetrathiomolybdate inhibits the reaction of cisplatin with human copper chaperone Atox1.
    Tian Y; Fang T; Yuan S; Zheng Y; Arnesano F; Natile G; Liu Y
    Metallomics; 2018 May; 10(5):745-750. PubMed ID: 29721562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel interaction of antioxidant-1 with TRAF4: role in inflammatory responses in endothelial cells.
    Das A; Sudhahar V; Ushio-Fukai M; Fukai T
    Am J Physiol Cell Physiol; 2019 Dec; 317(6):C1161-C1171. PubMed ID: 31553645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Copper chaperone Atox1 interacts with the metal-binding domain of Wilson's disease protein in cisplatin detoxification.
    Dolgova NV; Nokhrin S; Yu CH; George GN; Dmitriev OY
    Biochem J; 2013 Aug; 454(1):147-56. PubMed ID: 23751120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells.
    Blair BG; Larson CA; Adams PL; Abada PB; Safaei R; Howell SB
    Mol Pharmacol; 2010 Jun; 77(6):912-21. PubMed ID: 20194531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors.
    Qi J; Jin F; Xu X; Du Y
    Int J Nanomedicine; 2021; 16():1435-1456. PubMed ID: 33654395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs.
    Howell SB; Safaei R; Larson CA; Sailor MJ
    Mol Pharmacol; 2010 Jun; 77(6):887-94. PubMed ID: 20159940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.